Press release
mTOR Inhibitors Market Report 2024: Strategies And Recent Developments | Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, LC Laboratories
mTOR Inhibitors Market Characteristics
The Business Research Company offers in-depth market insights through mTOR Inhibitors Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The mtor inhibitors market size has grown strongly in recent years. It will grow from $7.11 billion in 2023 to $7.52 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to oncology treatment advancements, renal cell carcinoma treatment, transplantation medicine, clinical research and drug development, immunosuppressive applications..
The mtor inhibitors market size is expected to see strong growth in the next few years. It will grow to $9.3 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to expanding oncology indications, advancements in precision medicine, rising transplantation cases, chronic disease management, increasing geriatric population.. Major trends in the forecast period include exploration of neuroprotective effects, utilization in transplant medicine, rising interest in metabolic disorders, collaborations for drug development, global health initiatives for rare diseases..
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=10860&type=smp
Market Segmentation:
The mtor inhibitors market covered in this report is segmented -
1) By Product Type: Rapamune, Afinitor, Torisel, Zortress, Other Product Types
2) By Indication: Oncology, Immunosuppressant, Organ Transplantation, Other Indications
3) By Route of Administration: Oral, Intravenous
4) By Application: Tumor Treatment, Kidney Transplant, Other Applications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Major Driver - Rising Kidney Disease Cases Boost Prospects For Mtor Inhibitors Market
The rise in the prevalence of kidney diseases is expected to propel the growth of the mTOR inhibitors market going forward. Kidney disease refers to a condition that causes the organs to gradually deteriorate and lose their ability to function. mTOR inhibitors are used in the treatment of various kidney illnesses. Immunosuppressive treatments, including mTOR inhibitors such as sirolimus and everolimus are used to prevent renal allograft rejection. As the prevalence of kidney diseases continues to rise globally, the demand for mTOR inhibitors is increasing. For instance, in April 2022, according to the International Society of Nephrology, a US-based global professional association, there are 843.6 million people worldwide who are affected by stages 1 to 5 of kidney diseases. Over 800 million people globally or 10% of the overall population suffer from chronic renal disease, a degenerative ailment. Therefore, the rise in the prevalence of kidney diseases will propel the growth of the mTOR inhibitors market.
Competitive Landscape:
Major companies operating in the mtor inhibitors market report are Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, LC Laboratories, Exelixis Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Accord Healthcare Inc., Par Pharmaceutical, AbbVie Inc., GlaxoSmithKline plc, Biocon Limited, Alkem Laboratories Ltd., Gland Pharma Ltd., Apotex Inc., Glenmark Pharmaceuticals Ltd., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co. Inc., AmpliPhi Biosciences Corporation, Melinta Therapeutics Inc., Aduro Biotech Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report
Top Trend - Cambrian Biopharma And Novartis Strategic Alliances Advance Mtor Inhibitors Research
Partnership and collaboration are the key trends gaining popularity in the mTOR inhibitors market. Companies are partnering to gain a lead in the mTOR inhibitors market. For instance, in October 2022, Mirati Therapeutics, Inc., a US-based clinical-stage targeted oncology company collaborated with Aadi Bioscience, Inc. for an undisclosed amount. This collaboration aims to leverage the combination of the two drugs to potentially offer enhanced advantages for patients with KRAS G12C mutant NSCLC and other types of cancers. Aadi Bioscience, Inc is a US-based biopharmaceutical company in the commercial stage, dedicated to developing precision therapies for genetically defined cancers. Their goal is to provide treatments to cancer patients with mTOR pathway driver alterations. Additionally, in February 2022, Cambrian Biopharma, a US-based longevity biotech company with multiple assets, signed a licensing agreement with Novartis for an undisclosed amount. The purpose of this agreement is to progress a set of innovative and specific compounds developed and characterized by Novartis. These compounds have been specifically designed to target the mechanistic target of the rapamycin (mTOR) pathway. Novartis is a Switzerland-based company that researches, develops, manufactures, and markets healthcare products, specializing in oncology and other rare diseases.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. mTOR Inhibitors Market Characteristics
3. mTOR Inhibitors Market Trends And Strategies
4. mTOR Inhibitors Market - Macro Economic Scenario
5. mTOR Inhibitors Market Size And Growth
…..
27. mTOR Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release mTOR Inhibitors Market Report 2024: Strategies And Recent Developments | Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, LC Laboratories here
News-ID: 3431011 • Views: …
More Releases from The Business research company
Miticides For Fruits and Vegetablesr Market 2024 Report By Key Companies, Region …
The miticides for fruits and vegetables market size has grown strongly in recent years. It will grow from $1.01 billion in 2023 to $1.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to growing awareness of environmental impact, integrated pest management (ipm) adoption, market demand for quality produce, advancements in crop protection techniques, global expansion…
Telecom Tower Market Trends, Top Companies, Share, Growth And Forecast 2033
The telecom tower market size has grown rapidly in recent years. It will grow from $52.6 billion in 2023 to $59.41 billion in 2024 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing mobile data usag*, telecom infrastructure sharing practices, government initiatives, carrier competition and network densification, urbanization and population growth.
The telecom tower market size is expected…
Target Acquisition Systems Market Report 2024 | Size, Share, Growth, Trends, Ana …
The target acquisition systems market size has grown strongly in recent years. It will grow from $13.82 billion in 2023 to $14.72 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to military modernization programs, rise in threats and conflicts, shift towards network-centric warfare, integration of ai and machine learning, upgradation of existing systems.
The target acquisition…
Stroke Management Global Market Analysis, Trends, Growth, Research And Forecast …
The stroke management market size has grown strongly in recent years. It will grow from $36.94 billion in 2023 to $39.98 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to thrombolytic therapies, stroke prevention initiatives, rehabilitation techniques, telemedicine in stroke care, collaborative stroke networks.
The stroke management market size is expected to see strong growth in…
More Releases for Inhibitors
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market to Regist …
Vesicular monoamine transporter 2 (VMAT2) is a membrane-embedded protein that is responsible for uptake of monoamines neurotransmitters such as dopamine, serotonin, norepinephrine, and histamines into the synaptic vesicles in monoaminergic neurons. Vesicular monoamine transporter proteins 2 are expressed in the central nervous system (CNS) and plays the crucial role in the signaling process between the monoamine neurons. VMAT2 is the only transporter that carries the cytoplasmic dopamine into the vesicles.…
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to…
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy
1.1 Overview
1.2 History- From Tragedy to Breakthrough
Major Immune Checkpoints Proteins
2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development
2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development
Mechanism of Action of Immune Checkpoint Inhibitors
3.1 Cytotoxic T lymphocyte Antigen-4…
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity.
The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab…
Tumor Necrosis Factor Inhibitors Market & TNF Inhibitors Clinical Pipeline Outlo …
The search for the effective therapeutic approaches in the modulation of the TNF has been focus of the research efforts. Approximately 1 Million people in the worldwide either undergoing the treatment or have been treated with the TNF inhibitors which are available in the pharmaceutical market which surrounding the indications that include the rheumatoid arthritis, psoriatic arthritis, psoriasis and inflammatory bowel diseases.
The neutralization of the TNF signaling can be achieved…
